GLP1R and type 2 diabetes mellitus: In a pilot study in 12 patients without T2D and with HFrEF, a 5-week infusion of GLP-1 significantly improved LVEF (from 21 ± 3 to 27 ± 3%, p < 0.01), peak oxygen uptake (VO2peak from 10.8 ± 0.9 to 13.9 ± 0.6 mL/min/kg, p < 0.001), and 6-min walk distance (from 232 ± 15 to 286 ± 12 m, p < 0.001) when compared to standard therapy [9].